Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 4/20 | 0.40 |
| ▸ | AVPR1A | P37288 | 1/20 | 0.39 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.39 |
| ▸ | TIPARP | Q7Z3E1 | 1/20 | 0.38 |
| ▸ | TRPC5 | Q9UL62 | 1/20 | 0.38 |
| ▸ | TRPA1 | O75762 | 2/20 | 0.38 |
| ▸ | MALT1 | Q9UDY8 | 2/20 | 0.37 |
| ▸ | AKT1 | P31749 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8244439 | 0.90 | TRPV1 (0.42) | TRPV1AVPR1AHSD11B1TRPA1MALT1 | |
| SCHEMBL14086103 | 0.78 | TRPV1 (0.45) | TRPV1TRPA1 | |
| SCHEMBL4865173 | 0.77 | TRPV1 (0.50) | TRPV1HSD11B1TRPC5TRPA1MALT1 | |
| SCHEMBL8299219 | 0.72 | LMNA (0.59) | TRPV1HSD11B1TRPA1MALT1 | |
| SCHEMBL14086100 | 0.72 | MTOR (0.41) | — | |
| SCHEMBL8250785 | 0.71 | TRPV1 (0.45) | TRPV1TRPA1 | |
| SCHEMBL4870062 | 0.70 | TRPV1 (0.67) | TRPV1MALT1 | |
| SCHEMBL2849660 | 0.69 | TRPV1 (0.53) | TRPV1HSD11B1TRPA1MALT1 | |
| SCHEMBL14086094 | 0.69 | TRPV1 (0.48) | TRPV1TRPA1 | |
| SCHEMBL8499455 | 0.68 | ALDH1A1 (0.36) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7414131-B2 | Bicycloheteroarylamine compounds as ion channel ligands and uses thereof | RENOVIS, INC. (US) | 2008-08-19 | — | — | US | disclosed |
| US-7414131-B2 | Bicycloheteroarylamine compounds as ion channel ligands and uses thereof | RENOVIS, INC. (US) | 2008-08-19 | — | — | US | disclosed |
| US-7414131-B2 | Bicycloheteroarylamine compounds as ion channel ligands and uses thereof | RENOVIS, INC. (US) | 2008-08-19 | — | — | US | disclosed |
| US-7312330-B2 | Bicycloheteroarylamine compounds as ion channel ligands and uses thereof | RENOVIS, INC. (US) | 2007-12-25 | — | — | US | disclosed |
| US-7312330-B2 | Bicycloheteroarylamine compounds as ion channel ligands and uses thereof | RENOVIS, INC. (US) | 2007-12-25 | — | — | US | disclosed |
| US-7312330-B2 | Bicycloheteroarylamine compounds as ion channel ligands and uses thereof | RENOVIS, INC. (US) | 2007-12-25 | — | — | US | disclosed |
| WO-2006118598-A1 | BICYCLOHETEROARYLAMINE COMPOUNDS AS ION CHANNEL LIGANDS AND USES THEREOF | RENOVIS, INC. (US) | 2006-11-09 | — | — | WO | disclosed |
| EP-1697361-A1 | BICYCLOHETEROARYLAMINE COMPOUNDS AS ION CHANNEL LIGANDS AND USES THEREOF | Renovis, Inc. (US) | 2006-09-06 | — | — | EP | disclosed |
| US-20050277643-A1 | Bicycloheteroarylamine compounds as ion channel ligands and uses thereof | EVOTEC AG (DE) | 2005-12-15 | — | — | US | disclosed |
| US-20050215572-A1 | N-(4-tert-Butyl-phenyl)-[7-(3-chloro-pyridin-2-yl)-2-methoxymethyl-5,6,7,8-tetrahydro-pyrido[3,4-d]pyrimidin-4-yl]-amine; antiinflammatory agents treating pain, inflammation, traumatic injury, arthritis, Parkinson's disease, Alzheimer's disease, stroke, asthma, myocardial infarction | EVOTEC AG (DE) | 2005-09-29 | — | — | US | disclosed |
| WO-2005066171-A1 | BICYCLOHETEROARYLAMINE COMPOUNDS AS ION CHANNEL LIGANDS AND USES THEREOF | RENOVIS, INC. (US) | 2005-07-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050215572-A1 | N-(4-tert-Butyl-phenyl)-[7-(3-chloro-pyridin-2-yl)-2-methoxymethyl-5,6,7,8-tetrahydro-pyrido[3,4-d]pyrimidin-4-yl]-amine; antiinflammatory agents treating pain, inflammation, traumatic injury, arthritis, Parkinson's disease, Alzheimer's disease, stroke, asthma, myocardial infarction | PARK7, PTGIS, PTGES | TRPV1 224/4885AVPR1A 3738/4885HSD11B1 3676/4885 |
| US-20050277643-A1 | Bicycloheteroarylamine compounds as ion channel ligands and uses thereof | TRPV1, TRPV3, TRPA1 | TRPV1 1/4885AVPR1A 431/4885HSD11B1 4579/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.